Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CRCrinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc. (CRNX)

NASDAQ Global Select · Currency in USD
$84.95 ▲ +0.00 (+0.00%)
At close: Sep 1, 9:30 AM ET. Market closed.

Summary

Previous Close
$84.95
Open
$84.95
Day's Range
$84.95 – $84.95
52 Week Range
$32.30 – $85.01
Volume
0
Avg. Volume
3,255,497
Market Cap
$9.01B
Beta (5Y Monthly)
0.13
PE Ratio (TTM)
--
EPS (TTM)
-$4.75
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$84.86

Profile: Crinetics Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
594
CEO
R. Scott Struthers

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs).

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$1.20 · Revenue est. $21.04M
DateEst.Actual
Aug 3, 2026-$1.18-$1.14Beat
May 7, 2026-$1.22-$1.23Miss
Feb 26, 2026-$1.37-$1.29Beat
Nov 6, 2025-$1.27-$1.38Miss
Aug 7, 2025-$1.13-$1.23Miss
May 8, 2025-$0.99-$1.04Miss

Analyst view

Consensus price target
$84.86 ▼ -0.1%
Range $84.00 – $85.00
Rating: Buy
Buy 62% · Hold 38% · Sell 0%

Get free alerts on CRNX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.